Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

TBD, Turkey Clinical Trials

A listing of TBD, Turkey clinical trials actively recruiting patients volunteers.

RESULTS

Found (99) clinical trials

The purpose of the study is to evaluate the safety, tolerability and time-course profile of FVIII activity levels with adaptive doses of SB-525.

Phase

LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC

This is a Phase Ib/II open label clinical trial in patients with metastatic castration resistant prostate cancer. The objective of the phase Ib portion of the study is to establish the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of docetaxel (75 mg/m2 IV q21 days) and prednisone (5mg ...

Phase

Enzalutamide With and Without Ribociclib for Metastatic Castrate-Resistant Chemotherapy-Naive Prostate Cancer That Retains RB Expression

PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose of ribociclib in combination with 160 mg of enzalutamide. (Phase Ib) II. To determine efficacy with respect to the proportion of subjects that achieve a >= 50% reduction in prostate-specific antigen (PSA) at 12 weeks. (Phase II) SECONDARY OBJECTIVES: I. PSA ...

Phase

A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa

A clinical trial of AAV-RPGR retinal gene therapy for patients with X-linked retinitis pigmentosa

Phase

Focal Salvage HDR Brachytherapy for Locally Recurrent Prostate Cancer in Patients Treated With Prior Radiotherapy

The goal of any radiation treatment plan is to achieve maximal disease response with minimal toxicity. HDR brachytherapy offers a promising definitive treatment option in the setting of Locally Recurrent Prostate Cancer after prior definitive radiation, based on the limited data described above, with achievement of biochemical disease control in ...

Phase

Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants

Bone marrow CD34+ cells will be obtained in the operating room, transduced with the lentiviral vector that contains a normal copy of the c gene, and reinfused without any myeloreductive conditioning. Participants will be monitored for hematopoietic recovery from busulfan and for severe adverse events for 42 days. The primary ...

Phase

A clinical trial to evaluate treatments using Olaparib for patients

PRIMARY OBJECTIVES: I. Determine the maximum tolerated dose (MTD) of olaparib in combination with radium Ra 223 dichloride (radium-223). (Phase 1) II. Evaluate the radiographic progression-free survival (rPFS). (Phase 2) SECONDARY OBJECTIVES: I. Evaluate safety and tolerability as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. II. ...

Phase

Stem Cell Therapy Combined With NeuroRegen Scaffold in Patients With Erectile Dysfunction After Rectal Cancer Surgery

Erectile dysfunction (ED) is one of the commonest complications in men after rectal cancer treatment. The purpose of this study is to assess the safety and efficacy of autologous bone marrow mononuclear cells (BMMCs) or allogeneic human umbilical cord-derived mesenchymal stem cells (HUC-MSCs) combined with NeuroRegen scaffold transplantation in men ...

Phase

Efficacy of Repeat Stereotactic Radiation in Patients With Intraprostatic Tumor Recurrence

To date, no standard local treatment exists for patients with an intraprostatic recurrence after radiotherapy. A number of treatments options exist including: radical prostatectomy, brachytherapy, HIFU, cryotherapy, and stereotactic radiotherapy. These treatments are associated with a variety of genitourinary and gastrointestinal toxicities and complications. In recent years, stereotactic radiotherapy has ...

Phase

Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer

PRIMARY OBJECTIVES: I. To establish the safe and pharmacologically active doses of mifepristone and enzalutamide to use in combination. (Phase I) II. To determine if mifepristone in combination with enzalutamide prolongs time to prostate-specific antigen (PSA) progression compared to enzalutamide alone in patients with metastatic castration resistant prostate cancer. (Phase ...

Phase